pyridoxamine has been researched along with Atherogenesis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J | 2 |
| Tao, H | 2 |
| Yancey, PG | 2 |
| Leuthner, Z | 2 |
| May-Zhang, LS | 2 |
| Jung, JY | 2 |
| Zhang, Y | 2 |
| Ding, L | 2 |
| Amarnath, V | 2 |
| Liu, D | 2 |
| Collins, S | 2 |
| Davies, SS | 2 |
| Linton, MF | 2 |
| Wu, ET | 1 |
| Liang, JT | 1 |
| Wu, MS | 1 |
| Chang, KC | 1 |
| Kuzan, A | 1 |
| Chwiłkowska, A | 1 |
| Kobielarz, M | 1 |
| Pezowicz, C | 1 |
| Gamian, A | 1 |
| Engelen, L | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Serum Levels of Advanced Glycation End-products After Dietary Intervention in Hypertensive Patients: Study Protocol of a Randomized Clinical Trial.[NCT02848677] | Phase 2 | 120 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pyridoxamine and Atherogenesis
| Article | Year |
|---|---|
[Glycation of extracellular matrix proteins and its role in atherosclerosis].
Topics: Arteries; Atherosclerosis; Biomechanical Phenomena; Collagen; Connective Tissue; Elasticity; Extrace | 2012 |
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2013 |
2 other studies available for pyridoxamine and Atherogenesis
| Article | Year |
|---|---|
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation.
Topics: Aging; Animals; Aorta; Atherosclerosis; Body Weight; Collagen; Elasticity; Hypertrophy, Left Ventric | 2011 |